IGF-1 LR3 vs Wolverine Stack
IGF-1 LR3 and Wolverine Stack are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1, while Wolverine Stack is two-component repair blend — bpc-157 (10 mg) + tb-500 (10 mg) in one 20 mg vial — different molecular classes with different handling consequences; they call for different primary diluents (dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (denaturation and aggregation for IGF-1 LR3, methionine oxidation of the tb-500 component, accelerated by light and trapped air for Wolverine Stack), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
IGF-1 LR3 — origin
IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.
Wolverine Stack — origin
The Wolverine Stack combines the two most-studied tissue-repair peptides in a single 20 mg vial: BPC-157 (10 mg) and TB-500 (10 mg). It inherits the handling profile of both — the forgiving, gastric-derived BPC-157 and the oxidation-sensitive Thymosin-Beta-4 fragment TB-500 — so the blend is handled to the stricter of the two.
IGF-1 LR3 research themes
The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.
Widely used in cell-culture research as a growth-factor supplement.
Studied in muscle-biology research models.
The canonical downstream pathway examined in IGF-1 receptor research.
Wolverine Stack research themes
BPC-157 is studied around angiogenesis and growth-factor signalling; TB-500 around actin-mediated cell migration — non-overlapping routes into tissue repair.
Studied together in connective-tissue and wound-healing research designs where both mechanisms are of interest.
Because their mechanisms do not overlap, the two are frequently examined in parallel rather than as substitutes for one another.
IGF-1 LR3 handling
- Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
- Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
- Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
- Do not vortex; agitation denatures folded proteins at the air–liquid interface.
Wolverine Stack handling
- Reach room temperature before opening; the cake is hygroscopic.
- Add diluent gently down the wall and swirl; do not shake or vortex.
- Keep out of light and portion early, since every opening exposes the oxidation-sensitive TB-500 component to fresh air.
Both third-party tested
Every Popular Peptides batch of IGF-1 LR3 and Wolverine Stack is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
IGF-1 LR3 reference
Related comparisons
IGF-1 LR3 and Wolverine Stack are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.